The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...
Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...
Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer while it works to fend ...
Bourla said in a statement that Boshoff was “the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the ...
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback